Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after
autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab
is an antibody that has been engineered to attach to two target cells in the immune system: T
cells that normally perform tasks like killing virus-infected cells, and cancerous B cells.
Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells
instead.